The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LZAGY | +13.23% | +13.79% | +2.62% | +806% |
| S&P | +14.5% | +93.32% | +14.09% | +608% |
Lonza Group AG is engaged in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment offers small molecule drug substances and intermediates related services. The Cell and Gene segment includes the Cell and Gene Technologies and Bioscience businesses. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.
If it's stability you're looking for, probably so.
Pierre-Alain Ruffieux will lead the contract development and manufacturing organization.
Currently no data to display
Currently no data to display.
Currently no data to display.
| Metric | YoY Change |
|---|
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
